AtriCure (ATRC) Releases Earnings Results, Beats Expectations By $0.01 EPS

AtriCure (ATRC) reported quarterly earnings results on Thursday, Apr-28-2016. The company said it had a profit of $-0.31 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.32. The company posted revenue of $35.90 million in the period, compared to analysts expectations of $35.74 million. The company’s revenue was up 19.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.19 EPS.

AtriCure opened for trading at $17.47 and hit $17.9 on the upside on Wednesday, eventually ending the session at $17.75, with a gain of 1.49% or 0.26 points. The heightened volatility saw the trading volume jump to 2,93,614 shares. Company has a market cap of $573 M.

In a different news, on Mar 9, 2016, Elizabeth D Krell (director) sold 10,000 shares at $16.91 per share price. According to the SEC, on Dec 7, 2015, Douglas J Seith (Chief Operating Officer) sold 5,000 shares at $21.55 per share price. On May 8, 2015, Karen P Robards (director) sold 2,650 shares at $22.18 per share price, according to the Form-4 filing with the securities and exchange commission.

AtriCure Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The Company’s Isolator Synergy System which includes its Isolator Synergy clamps generator and switchbox is used for the treatment of persistent and long-standing persistent Afib in patients who are undergoing open concomitant coronary artery bypass grafting and valve replacement or repair. The cryoICE cryosurgery product line offers a range of both single use and reusable cryoablation devices. The AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA). Its radiofrequency (RF) ablation products are indicated for the ablation of cardiac tissue. The Company sells enabling technologies including its Lumitip dissectors and Endoscopic Technologies Inc.’s (Estech) line of reusable cardiac surgery instruments.


Leave a Reply

AtriCure - Is it time to Sell?

Top Brokerage Firms are advising their investors on AtriCure. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.